

Paper No. _____
Filed December 1, 2017

**UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD**

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
INC., and AKORN INC.¹

Petitioners,

v.

ALLERGAN, INC.,

Patent Owner.

Case IPR2016-01127 (8,685,930 B2)

Case IPR2016-01128 (8,629,111 B2)

Case IPR2016-01129 (8,642,556 B2)

Case IPR2016-01130 (8,633,162 B2)

Case IPR2016-01131 (8,648,048 B2)

Case IPR2016-01132 (9,248,191 B2)

**COMMENTS OF *AMICI CURIAE* DEVA HOLDING A.S. IN RESPONSE
TO THE BOARD'S INVITATION FOR *AMICUS* BRIEFS REGARDING
THE TRIBE'S MOTION TO TERMINATE**

¹ Cases IPR2017-00576, IPR2017-00594, IPR2017-00578, IPR2017-00596, IPR2017-00579, IPR2017-00598, IPR2017-00583, IPR2017-00599, IPR2017-00585, IPR2017-00600, IPR2017-00586 and IPR2017-00601 have respectively been joined with the above-captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the above caption pursuant to the Board's Scheduling Order (Paper 10).

Table of Contents

I. IDENTITY OF INTEREST OF *AMICI CURIAE*.....1

II. ARGUMENT3

A. The Tribe’s and Allergan’s actions in related litigation belie their claims in these Board proceedings that Allergan and the Tribe lack identical interests, and Allergan cannot represent the Tribe in its absence.....3

B. The Tribe’s and Allergan’s actions in other related litigation belie their claims that Allergan and the Tribe lack identical interests, and Allergan cannot represent the Tribe in its absence.....5

III. CONCLUSION.....6

CERTIFICATE OF SERVICE.....7

I. IDENTITY OF INTEREST OF *AMICI CURIAE*

DEVA Holding A.S. (“DEVA”) is a Turkish company involved in a pending lawsuit in the United States District Court for the Eastern District of Texas filed by Allergan, Inc. (“Allergan”) against DEVA, Civil Action No. 2:16-cv-1447-WCB (“the Pending Litigation”). In this action, Allergan alleges that Deva’s proposed generic version of the Restasis® Product, which is the subject of an Abbreviated New Drug Application filed by DEVA with the United States Food and Drug Administration, will infringe United States Patent Nos. 8,629,111, 8,633,162, 8,642,556, 8,648,048, 8,685,930, and 9,248,191 (“the Patents-in-Suit”). DEVA asserts that the Patents-In-Suit are invalid or not infringed by its ANDA product. The Pending Litigation is in its early stages, with the parties presently engaged in fact discovery and trial set for October 15, 2018. Recently, Allergan and Deva jointly submitted a stipulation to the Court regarding claim construction, without participation of the Saint Regis Mohawk Tribe (“the Tribe”).

Because the Board provides limited procedural guidance regarding a filing of this nature, we respectfully submit these comments to assist the Board’s evaluation of the Tribe’s Motion to Terminate these IPR proceedings. In Paper 96, the Board authorized any interested *amici curiae* to file briefing on the pending Motion to Terminate by December 1, 2017. We certify that no party or its counsel

to the above-captioned Board proceedings authored these comments in whole or in part, no such party or its counsel contributed money intended to fund the preparation or submission of these comments, and no person other than the *amici* contributed money intended to fund the preparation or submission of these comments.

II. ARGUMENT

A. **The Tribe's and Allergan's actions in related litigation belie their claims in these Board proceedings that Allergan and the Tribe lack identical interests, and Allergan cannot represent the Tribe in its absence.**

Actions speak louder than words. In its Corrected Motion to Terminate (Dkt. 81 at 16), the Tribe argues that it is an indispensable party under the Board's identity-of-interest test. Specifically, the Tribe *says* that the Board cannot proceed "in the absence of the Tribe because Allergan and the Tribe do not have identical interests, and Allergan cannot represent the Tribe in its absence." (*Id.*) In support of that argument, the Tribe further says that claim construction positions "might" serve Allergan's interest differently than the Tribe's or that the Tribe might "desire to not risk the validity of the Patents-at-Issue." (*Id.* at 22.) Despite these hollow words, the most recent actions by Allergan and the Tribe in the Pending Litigation against DEVA speak volumes to the contrary.

In the Pending Litigation against DEVA, Allergan acted by filing a letter with the Court on September 8, 2017 stating that "[t]his morning, Allergan assigned its rights in a number of patents, including the patents-in-suit, to the Saint Regis Mohawk Tribe." (Pending Litigation, D.I. 44-1.) Allergan further states that "Allergan does not anticipate that this assignment will have any impact on the litigation or the issues before the Court, other than it expects to join the Tribe as a co-plaintiff in due course." (*Id.*) Here is where Allergan's and the Tribe's

inconsistent positions before this Board and the district court become apparent. On one hand, in the Pending Litigation against DEVA, Allergan itself informs the Court that it does not anticipate that the Tribe's involvement "will have any impact on the litigation or the issues before the Court." But on the other hand, the Tribe argues to this Board that it may need to take claim construction positions competing with Allergan.

Just as important, since the September 8, 2017 letter to the Court, neither Allergan or the Tribe have asked that the Tribe be joined as a co-plaintiff to the Pending Litigation. These actions by Allergan and the Tribe demonstrate that they understand and agree that Allergan can and is, in fact, currently representing the Tribe's identical interests in matters relating to the patents-in-suit. This is also confirmed by the License Agreement stating that Allergan, not the Tribe, retains control over litigation. (EX2087 §§ 5.1.1., 5.2.2., 5.3.)

The most telling example showing that, for all practical purposes, Allergan's and the Tribe's interests are identically aligned concerns the recent joint filing by Deva and Allergan regarding claim construction in the Pending Litigation. Even after the filing of the Corrected Motion to Terminate on September 22, 2017 (Dkt. 81) and corresponding Reply brief on October 20, 2017 (Dkt. 93) with the Board, on November 10, 2017, Deva and Allergan filed a Joint Motion for Stipulation Concerning Claim Construction with the court in the Pending Litigation. (Pending

Litigation, D.I. 47). Noticeably absent from this filing is the Tribe as a named party, let alone any allegation that the Tribe may potentially have a competing claim construction. This filing action by Allergan, coupled with the filing inaction by the Tribe on a substantive issue, clearly demonstrates that the Tribe's interests are identically aligned with those of Allergan, despite their hollow arguments to the contrary before the Board.

B. The Tribe's and Allergan's actions in other related litigation belie their claims that Allergan and the Tribe lack identical interests, and Allergan cannot represent the Tribe in its absence.

The words of Allergan and the Tribe before the Board are not only hollow and inconsistent with their actions in the Pending Litigation against DEVA, they are equally inconsistent with actions taken in other district court litigations. As recognized by the Tribe in its Reply (Dkt. 93 at 4), the United States District Court for the Eastern District of Texas recently invalidated all asserted claims of the Patents-In-Suit in a different action before Judge Bryson, *Allergan et al. v. Teva et al.*, 2:15-cv-1455-WCB (E.D.Tex.). (EX. 1165.) In response to this judgment, the Tribe says "Allergan could choose not to appeal the district court opinion and thereby avoid paying any additional royalties to the Tribe, which potentially total more than \$100,000,000." (Dkt. 93 at 4). Those arguments to this Board again are inconsistent with the *actions* of Allergan and the Tribe, when a mere seven days later they jointly filed a notice of appeal with the Federal Circuit on October 27,

2017. *Allergan et al. v. Teva et al.*, 2:15-cv-1455-WCB (E.D.Tex.) (D.I. 527).

This again demonstrates that the interests of Allergan and the Tribe are identical for all practical purposes and the Tribe's Motion to Terminate should be denied.

III. CONCLUSION

For the foregoing reasons, we respectfully submit these comments and respectfully request the Board to deny the Tribe's Motion to Terminate.

Respectfully submitted,

Dated: December 1, 2017

/Joseph E. Cwik/

Joseph E. Cwik

Reg. No. 38,421

joe@amintalati.com

Shashank Upadhye

shashank@amintalati.com

Erin R. Conway

erin@amintalati.com

AMIN TALATI UPADHYE LLP

100 S. Wacker Dr., Suite 2000

Chicago IL 60606

Tel: (312) 466-1033

Fax: (312) 884-7352

*Attorneys for DEVA Holding
A.S.*

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §42.6(e)(4) and 42.205(b), the undersigned certifies that on December 1, 2017, a complete and entire copy of COMMENTS OF AMICI CURIAE DEVA HOLDING A.S. IN RESPONSE TO THE BOARD'S INVITATION FOR AMICUS BRIEFS REGARDING THE TRIBE'S MOTION TO TERMINATE was provided, via electronic service, to the Petitioners and Patent Owners by serving the correspondence address of record as follows:

Steven W. Parmelee
Michael T. Rosato
Jad A. Mills
WILSON SONSINI GOODRICH & ROSATI
701 Fifth Avenue, Suite 5100
Seattle, WA 98104-7036
sparmelee@wsgr.com
mrosato@wsgr.com
jmills@wsgr.com

Wendy L. Devine
WILSON SONSINI GOODRICH & ROSATI
One Market Street, Spear Tower Floor 33
San Francisco, CA 94105-1126
wdevine@wsgr.com

Douglas H. Carsten
WILSON SONSINI GOODRICH & ROSATI
12235 El Camino Real, Suite 200
San Diego, CA 92130
dcarsten@wsgr.com

Richard Torczon
WILSON SONSINI GOODRICH & ROSATI

1700 K Street NW, 5th Floor
Washington, DC 20006
rtorczon@wsgr.com

Brandon M. White
Crystal Canterbury
Charles G. Curtis, Jr.
Jennifer MacLean
Benjamin S. Sharp
Shannon M. Bloodworth
PERKINS COIE LLP
700 13th Street NW
Washington DC 20005
bmwhite@perkinscoie.com
ccanterbury@perkinscoie.com
ccurtis@perkinscoie.com
jmaclean@perkinscoie.com
bsharp@perkinscoie.com
sbloodworth@perkinscoie.com

Eric D. Miller
PERKINS COIE LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
emiller@perkinscoie.com
Attorneys for Mylan Pharmaceuticas, Inc.

Michael R. Dzwonczyk
Azy S. Kokabi
Travis B. Ribar
SUGHRUE MION, PLLC
2100 Pennsylvania Ave., NW, Suite 800
Washington, DC 20037
mdzwonczyk@sughrue.com
akokabi@sughrue.com
tribar@sughrue.com
Attorneys for Akorn Inc.

Gary J. Speier
Mark D. Schuman

CARLSON, CASPERS, VANDENBURGH, LINDQUIST & SCHUMAN, P.A.

225 South Sixth Street, Suite 4200
Minneapolis, MN 55402
gspeier@carlsoncaspers.com
mschuman@carlsoncaspers.com
IPRCyclosporine@carlsoncaspers.com
Attorneys for Teva Pharmaceuticals

Alfonso Chan
achan@shorechan.com
Michael Shore
mshore@shorechan.com
Christopher Evans
cevans@shorechan.com
SHORE CHAN DEPUMPO LLP
901 Main Street, Suite 3300
Dallas, TX 75201
Tel: (214) 593-9110
Fax: (214) 593-9111

Marsha Schmidt
Attorney at Law
14928 Perrywood Drive
Burtonsville, MD 20866
marsha@mkschmidtlaw.com
Tel: (301) 949-5176
Attorneys for Saint Regis Mohawk Tribe

Dorothy P. Whelan
Michael Kane
Susan Morrison Colletti
Robert M. Oakes
Jonathan Singer
Fish & Richardson P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Email: IPR13351-0008IP1@fr.com
Email: IPR13351-0008IP2@fr.com

Email: IPR13351-0008IP3@fr.com

Email: IPR13351-0008IP4@fr.com

Email: IPR13351-0008IP5@fr.com

Email: IPR13351-0008IP6@fr.com

PTABinbound@fr.com

Attorneys for Allergan, Inc.

Respectfully submitted,

Dated: December 1, 2017

/Joseph E. Cwik/

Joseph E. Cwik

Reg. No. 38,421

joe@amintalati.com

Shashank Upadhye

shashank@amintalati.com

Erin R. Conway

erin@amintalati.com

AMIN TALATI UPADHYE LLP

100 S. Wacker Dr., Suite 2000

Chicago IL 60606

Tel: (312) 466-1033

Fax: (312) 884-7352

Attorneys for DEVA Holding

A.S.